Results 201 to 210 of about 37,077 (282)

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]

Front Oncol
Akiyama H, Kakiuchi S, Sakamoto A, Tomigaki N, Fujioka S, Harima I, Niwa R, Takagi I, Kozuki Y, Miyata Y, Yoshihara K, Yoshihara S, Iwata N.   +12 more
europepmc   +1 more source

New antibody approaches to lymphoma therapy [PDF]

, 2014

core   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source

Pfs48/45 nanobodies block Plasmodium falciparum transmission. [PDF]

PLoS Pathog
Lyons FMT, Chmielewski J, Gabriela M, Chan LJ, Tong J, Adair A, Zeglinski K, Gouil Q, Dietrich MH, Tham WH.   +9 more
europepmc   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma. [PDF]

Medicina (Kaunas)
Tang TF, Cheong CS, Looi CY, Wong WF, Gan GG.   +4 more
europepmc   +1 more source

A Generalized Minimal PBPK‐PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that ...
Phillip Spinosa, Louis Joslyn, Saroja Ramanujan, Kapil Gadkar, Iraj Hosseini   +4 more
wiley   +1 more source

IgE based therapeutics are an emerging modality in cancer treatment. [PDF]

Discov Oncol
Kumari S, Ghosh S, Doerner A.
europepmc   +1 more source

Nanobiotechnology‐Based Approaches for Uveal Melanoma Treatment

SmartMat, Volume 7, Issue 1, February 2026.
Emerging platforms for uveal melanoma combine precision drug delivery, ROS‐amplifying modalities, and nucleic acid transport to overcome ocular barriers and immunosuppressive niches. Targeted nanoparticles, virus‐like constructs, and injectable depots enable localized activation, controlled release, and gene‐level reprogramming.
Nadezhda A. Pechnikova, Ioannis Iliadis, Malamati Poimenidou, Chrysi Patsidou, Maria Zafeiriou‐Chatziefraimidou, Diamantis D. Almaliotis, Ioannis T. Tsinopoulos, Ivan V. Zelepukin, Alexey V. Yaremenko   +8 more
wiley   +1 more source